drugset
drugset / Trial / NCT05559125

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

NCT05559125 ↗

Phase 1 Terminated 50 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
Non-randomizedSequentialQuadruple-blindTreatment

Summary

An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.

Timeline

Start
2022-11-08
Primary completion
2024-03-26
Completion
2024-03-26

Outcome

Outcome not reported

Stopped: “Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.”

Drugs

EvaluationDrugModalityDoseRoute
Subject GREZIPRUBART Monoclonal antibody — Intravenous
Subject STSA-1005 Unknown — Intravenous

Indications

No indication recorded.